Date:1/7/2011

intentions. Such statements include, without limitation, statements regarding the anticipated benefits of the acquisition and Interlace's products. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated. Risks and uncertainties that may affect the Company's ability to cause actual results to vary materially, include, among others: problems may arise with the ability to successfully integrate the businesses of Hologic and Interlace, which may result in the combined company not operating as effectively and efficiently as expected; the Company may not be able to achieve the expected synergies from the acquisition or it may take longer than expected to achieve those synergies; the early stage of development of Interlace and its products; reimbursement risks relating to the use of Interlace's products; the acquisition may involve unexpected costs or unexpected liabilities, or the effects of purchase accounting may be different from the Company's expectations; risks related to the use and protection of Interlace's intellectual property and expenses and uncertainties relating to litigation with respect thereto. Moreover, the combined business of Interlace may be adversely affected by future legislative, regulatory, or tax changes as well as other economic, business and/or competitive factors. The risks included above are not exhaustive. Other factors that could adversely affect the Company's business and prospects are described in the Company's filings with the Securities and Exchange Commission. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such statements are based.Contact:

Deborah Gordon

Lindsay PhilbrickVice President, Investor Relati
'/>"/>

SOURCE Hologic, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Hologic to Release First Quarter Fiscal 2011 Operating Results on Monday, January 31, 2011
2. Hologic to Participate in Three Investor Conferences
3. Hologic Encourages Health Professionals to Get the Facts About Womens Imaging at RSNA 2010
4. Hologic Announces Fourth Quarter and Fiscal 2010 Operating Results
5. Hologic Announces Long-term, Five-year Results from MammoSite® ASBS Registry Study
6. Hologic to Host Investor Presentation at RSNA 2010
7. Hologic to Release Fourth Quarter Fiscal 2010 Operating Results on Monday, November 8, 2010
8. Hologics Selenia Dimensions (3-D) Digital Mammography Tomosynthesis System Receives Favorable Votes From FDA Advisory Panel
9. Hologic to Present at the 2010 Morgan Stanley Global Healthcare Conference
10. Ethicon Endo-Surgery Announces Agreement with Hologic Inc. To Resolve Patent Disputes
11. Hologic Announces Decision in Patent Infringement Suit